US Earnings Financial Results SEC Filings — March 23, 2026

23-03-2026

KiNRG, Inc., a company with no reported revenue, reported a significantly widened consolidated net loss of $2.7M for the year ended December 31, 2025, compared to $1.35M in 2024, primarily due to operating expenses nearly doubling to $2.36M from $1.21M, alongside increased stock-based compensation of $1.26M. However, the cash position improved dramatically to $328K from $23K, total assets grew to $338K from $48K, liabilities decreased 20% to $884K, and stockholders' deficit narrowed to ($546K) from ($1.05M), bolstered by $1M in financing activities including stock sales and warrant exercises. Losses from discontinued operations also worsened to $317K from $105K.

• ·No revenue reported in either FY2025 or FY2024.
• ·Net cash used in operating activities improved to $699K from $897K YoY.
• ·Derecognition of subsidiary in FY2025 resulted in $351K adjustment to non-controlling interest.
• ·Common stock issuances in FY2025 included $750K for cash, $250K warrant exercises, and non-cash issuances for services ($1.12M), director fees ($150K), officer salaries ($180K), and note conversion ($250K).
• ·Filing date: March 23, 2026, for period ended December 31, 2025.
• ·Auditor: Independent Registered Public Accounting Firm (PCAOB ID: 2738).

23-03-2026

Aterian, Inc. reported net revenue of $69.0M for the year ended December 31, 2025, down 30.4% YoY from $99.0M, driven by a 32.4% decline in direct sales while wholesale revenue grew 88.4% to $3.2M; however, most product segments declined sharply, including housewares down to $14.9M from $22.5M and heating/cooling to $13.9M from $26.4M, with essential oils remaining nearly flat. Gross profit fell 36.3% to $39.2M amid a drop in gross margin to 56.8% from 62.1%, and despite operating expenses decreasing to $57.1M, a $3.8M impairment loss contributed to operating loss widening 52.0% to $18.0M. Net loss increased 60.0% to $19.0M.

• ·Heating, cooling and air quality revenue: $13.9M in 2025 (down from $26.4M in 2024)
• ·Kitchen appliances revenue: $8.5M in 2025 (down from $9.6M in 2024)
• ·Health and beauty revenue: $10.6M in 2025 (down from $13.5M in 2024)
• ·Essential oils and related accessories revenue: $12.1M in 2025 (down slightly from $12.7M in 2024)
• ·Interest expense, net declined 10.3% to $0.9M

23-03-2026

Cartesian Growth Corp III reported net income of $6.2M for the year ended December 31, 2025, driven by $7.4M in interest income from investments held in the Trust Account totaling $283.4M from 27.6M Class A ordinary shares at ~$10.27 per share, with total assets increasing to $284.2M from $0.3M at December 31, 2024. However, the company recorded an operating loss of $1.2M from general and administrative costs, and shareholders' deficit stood at $13.2M, improved from $17.6K but still negative. Total liabilities rose to $14.0M, primarily due to a $13.1M deferred underwriting fee.

• ·Company inception date: October 29, 2024
• ·Filing date: March 23, 2026
• ·Auditor: Independent Registered Public Accounting Firm (PCAOB ID Number 199)

23-03-2026

Core Laboratories Inc. reported total revenue of $527M in 2025, up a modest 0.5% YoY from $524M, driven by 2.9% growth in services to $399M, while product sales declined 6.3% to $127M. Operating income fell 3.6% to $56M and net income attributable to the company decreased 5.5% to $30M with diluted EPS at $0.63, down 4.5%. Free cash flow was $26M, down sharply from $44M, though long-term debt net was reduced to $110M from $126M.

• ·Current ratio declined to 2.02:1 in 2025 from 2.16:1 in 2024.
• ·Debt to EBITDA ratio improved to 1.20:1 in 2025 from 1.37:1 in 2024.
• ·Credit facility balance reduced to $3M in 2025 from $18M in 2024.
• ·Senior Notes maturities: Series A 2021 at 4.09% due Jan 12, 2026 ($45M); others unchanged.
• ·Accounts receivable allowance for credit losses increased to $6.3M in 2025 from $3.2M in 2024.
• ·Inventories decreased to $54M in 2025 from $59M in 2024.

23-03-2026

The 10-K annual report includes multiple tables asserting compliance with Regulation AB Item 1122(d) servicing criteria for asset-backed securities by parties including Midland, an Asserting Party, Special Servicer, and CWCAM. Most applicable criteria across general servicing, cash collection, investor reporting, and pool asset administration are marked as performed directly (X) or by vendors/subservicers, while numerous others are designated N/A or not performed by the asserting party. No material noncompliance is noted, with specific applicability for investor reports on Platforms A and B, and loss mitigation actions.

• ·Compliance assertions cover timeframes such as deposits/postings within 2 business days, reconciliations within 30 calendar days, and resolution of reconciling items within 90 calendar days.
• ·Several criteria like back-up servicer maintenance (1122(d)(1)(iii)) and external enhancements (1122(d)(4)(xv)) are consistently N/A across tables.
• ·Investor reporting criteria (1122(d)(3)(i)) are applicable, but subparts (B),(C),(D) N/A in some tables; fully N/A for remittances in others.

23-03-2026

The 10-K filing includes Appendix B asserting compliance with Rule 1122(d) servicing criteria for asset-backed securities transactions involving pool assets and mortgage loans. Various parties, including the Company, Special Servicer, CoreLogic, KeyBank, and Asserting Party, indicate which criteria are performed directly, by responsible vendors, by non-responsible parties, or marked as inapplicable/not performed, with most general servicing, cash collection, and pool asset administration criteria covered. However, certain criteria such as back-up servicer maintenance (1122(d)(1)(iii)) and specific investor reporting/remittances (e.g., 1122(d)(3)(i)-(iv)) are frequently noted as not performed or inapplicable by multiple parties.

• ·Filing date: March 23, 2026
• ·Common timeframes in criteria: deposits/postings within 2 business days; reconciliations within 30 calendar days; resolution of reconciling items within 90 calendar days; escrow analysis annually
• ·Inapplicable/not performed criteria include back-up servicer requirements (1122(d)(1)(iii)) across multiple parties and investor reporting sub-criteria (1122(d)(3)(i)(B)-(D))

23-03-2026

This 10-K filing includes servicing compliance assessments under Regulation AB Item 1122(d) for asset-backed securities, where servicers such as Midland and KeyBank assert that most applicable criteria are performed directly or by responsible vendors, with some marked N/A or not performed by parties like PBLS and the Asserting Party. No material instances of noncompliance are disclosed across general servicing, cash collection, investor reporting, and pool asset administration categories. The assessments cover standard timeframes like deposits within 2 business days and reconciliations within 30-90 days.

• ·Multiple criteria marked N/A (e.g., 1122(d)(1)(iii) back-up servicer, investor remittances for some parties)
• ·KeyBank performed directly criteria including loss mitigation (1122(d)(4)(vii)) and escrow fund handling (1122(d)(4)(x))
• ·Several criteria not performed by PBLS or retained subservicers (e.g., all cash collection and most pool asset administration)

23-03-2026

Appendix B of the 10-K provides compliance assertions for servicing criteria under Regulation AB 1122(d) for asset-backed securities transactions. The Company and related entities (including Special Servicer, PBLS1, and CoreLogic) confirm direct performance or oversight of most criteria in general servicing considerations, cash collection and administration, and pool asset administration. However, numerous investor remittances and reporting criteria (e.g., 1122(d)(3)(i)-(iv)) are designated as not performed by the Company, subservicers, or retained vendors, indicating they are inapplicable to their roles.

• ·Compliance assessed throughout the reporting period ending prior to March 23, 2026 filing.
• ·Key timeframes include deposits/postings within 2 business days, reconciliations within 30 calendar days (resolved within 90 days), escrow analysis annually, and returns within 30 calendar days.

23-03-2026

Finwise Bancorp reported net income of $16.1M for the year ended December 31, 2025, up 26% from $12.7M in 2024, fueled by non-interest income surging 160% to $58.5M and net interest income growing 23% to $72.2M, alongside total assets expanding 31% to $977M and deposits rising 38.5% to $755M. However, provisions for credit losses ballooned to $38.6M from $11.6M, non-interest expenses increased 33% to $70.3M, net interest margin declined to 9.23% from 9.99%, and total equity to assets ratio fell to 19.8% from 23.3%. Segment-wise, BaaS contributed strongly with $10.5M net income, but Traditional Banking net income was $2.9M.

• ·BaaS segment net income $10.5M, Traditional Banking $2.9M, Treasury/Other $2.7M.
• ·Loans held-for-investment net grew 20.9% to $541.6M.
• ·Credit enhancement income $23.9M (up 21,453%), but related expenses surged (servicing +112,135%, guarantee +111,846%).
• ·Average yield on loans held-for-investment declined to 12.17% from 12.27%, net of credit enhancement to 10.35% from 12.27%.

23-03-2026

Unknown Company's 10-K filed on March 23, 2026, includes Appendix B assessing compliance with Regulation AB servicing criteria under 1122(d) for asset-backed securities. The company directly performs or oversees via responsible vendors most criteria in general servicing considerations, cash collection, and pool asset administration. However, multiple investor remittances and reporting criteria (e.g., 1122(d)(3)(i)(B)-(D), (ii)-(iv)) are not performed by the company or its subservicers, back-up servicer maintenance is inapplicable, and certain pool asset safeguards are handled by non-responsible parties.

• ·Back-up servicer requirements (1122(d)(1)(iii)) marked as not performed.
• ·Fidelity bond and errors/omissions policy (1122(d)(1)(iv)) in effect as required.
• ·Pool asset documents safeguarding (1122(d)(4)(ii)) not performed by company or subservicers in some tables.
• ·External enhancements/support (1122(d)(4)(xv)) inapplicable.

23-03-2026

This 10-K filing includes servicing criteria compliance assessments under Regulation AB Rule 1122(d) for asset-backed securities transactions involving servicers such as Midland, PBLS, and CWCAM. Multiple tables indicate that most applicable criteria are performed directly by the servicers or via responsible vendors, with several criteria marked as N/A or inapplicable due to transaction specifics. No material non-compliance issues are noted across general servicing, cash collection, investor reporting, and pool asset administration categories.

• ·Compliance tables reference standard timeframes such as deposits within 2 business days, reconciliations within 30 calendar days, and resolution of reconciling items within 90 calendar days.
• ·Certain criteria like back-up servicer maintenance (1122(d)(1)(iii)) and investor remittances (1122(d)(3)(ii)-(iv)) are frequently N/A across servicers.

23-03-2026

Unknown Company's 10-K annual filing includes Appendix B, a servicing compliance assessment under Regulation AB Item 1122, confirming the company directly performs most servicing criteria in areas like general servicing considerations, cash collection, and pool asset administration. However, several investor remittances and reporting criteria (e.g., 1122(d)(3)(i)(B)-(D), (ii)-(iv)) are marked as inapplicable or not performed by the company or its retained vendors/subservicers, with some handled by non-responsible parties. Vendors such as CoreLogic and PBLS1 provide assertions for their respective roles in specific criteria.

• ·Back-up servicer maintenance (1122(d)(1)(iii)) is not performed.
• ·Pool asset documents safeguarding (1122(d)(4)(ii)) is inapplicable in some assertions.
• ·Filing date: March 23, 2026

23-03-2026

The 10-K annual report includes Appendix B, which assesses compliance with Regulation AB Servicing Criteria (1122(d)) for asset-backed securities transactions, detailing which criteria are performed directly by the company, by responsible vendors, by non-responsible parties, or not performed/inapplicable. Compliance is affirmed for many general servicing, cash collection, pool asset administration, and investor reporting criteria, but numerous items (e.g., back-up servicer maintenance, certain investor remittances, and pool asset safeguarding) are marked as not performed or inapplicable across various servicer tables. Platforms A and B show partial applicability for investor reporting, with some criteria applicable only to Platform A.

• ·Filing date: March 23, 2026
• ·Multiple tables assess servicing criteria across different servicers/entities, with footnotes like X1, X2, X3, X4 indicating specifics
• ·Criteria such as 1122(d)(1)(iii) (back-up servicer) consistently marked as not performed or inapplicable

23-03-2026

For the year ended December 31, 2025, total terminal revenue declined 1.2% YoY to $319.9M from $323.6M, driven by sharp drops in Brownsville terminals (-28.4%) and central services (-34.3%), though offset by gains in Gulf Coast (+3.3%) and River terminals (+10.4%). Product sales fell 14.0% to $326.1M with gross margin slightly down 2.7% to $22.3M, while net cash from operations decreased 40.5% to $54.8M amid higher financing outflows.

• ·Midwest terminals revenue flat at -1.7% YoY to $11.1M.
• ·Southeast terminals revenue nearly flat at -1.1% YoY to $74.0M.
• ·Net cash provided by investing activities swung to $130.3M inflow from $67.6M outflow.
• ·Net cash used in financing activities increased to $180.8M from $24.0M.

23-03-2026

SUNation Energy reported FY2025 sales of $71.9M, up 26% YoY from $56.9M, driven by residential contracts (+31% to $40.2M in one segment and +31% to $21.0M in another), with gross profit rising 35% to $27.5M; however, SG&A expenses remained flat at ~$27M (38% of sales), total operating expenses declined only 11%, and the company posted a net loss of $10.9M (improved 31% YoY from $15.8M but widened by fair value losses on warrant liability of $7.5M). Balance sheet strengthened with cash surging to $7.2M from $0.8M, current liabilities dropping 43% to $15.4M, and stockholders' equity rising to $24.3M from $8.5M, aided by debt reductions.

• ·No goodwill or intangible impairments in FY2025 (vs $3.1M and $0.75M in FY2024)
• ·Fair value remeasurement of warrant liability loss of $7.5M in FY2025 (673% worse YoY)
• ·Reverse stock split 1-for-200 effective April 21, 2025; prior periods adjusted
• ·Basic net loss per share improved to -$4.38 from -$10,110.93 (adjusted)

23-03-2026

Unknown Company's 10-K filing includes assessments of compliance with Regulation AB Item 1122(d) servicing criteria for asset-backed securities by multiple servicers including Midland, Special Servicer, CoreLogic, and the Company itself. Most applicable criteria are marked as performed directly or by responsible vendors with no reported deficiencies, while numerous criteria are designated N/A or inapplicable. Compliance covers areas like cash collection, investor reporting, and pool asset administration throughout the reporting period.

• ·Numerous servicing criteria marked N/A, including back-up servicer maintenance (1122(d)(1)(iii)), investor remittances (1122(d)(3)(ii)-(iv)), and external enhancements (1122(d)(4)(xv)).
• ·Certain criteria performed by vendors for which the servicer is responsible, such as monitoring third-party performance (1122(d)(1)(ii)).
• ·Timeframes in criteria include deposits/postings within 2 business days, reconciliations within 30 calendar days, and resolution of reconciling items within 90 calendar days.

23-03-2026

Ashford Hospitality Trust's total revenue declined 5.8% YoY to $1.10B in 2025 from $1.17B in 2024, driven by lower rooms revenue ($826M, down 7.3%) and flat other segments, while total hotel expenses fell 5.8% to $768M providing some relief. Net loss attributable to the company widened significantly to $180M from $60M, with operating income dropping 55% to $116M and Adjusted EBITDAre decreasing 6.2% to $221M amid higher impairment charges ($68M, up 14%). RevPAR slipped 0.9% to $131.68 despite occupancy rising slightly to 70.3%, and Adjusted FFO worsened to -$34M from -$23M.

• ·Total hotel revenue $1.10B in 2025 (down 5.8% YoY), Rooms revenue $826M (down 7.3%), Food and beverage $208M (down 2.4%).
• ·Impairment charges $68M in 2025 (up 14% YoY from $59M).
• ·Stockholders’ equity deficit deepened to -$626M from -$419M.
• ·Debt associated with hotels in receivership $273M at Dec 31 2025 (down from $315M).

23-03-2026

The 10-K filing dated March 23, 2026, includes Appendix B assessing compliance with Regulation AB Rule 1122(d) servicing criteria for asset-backed securities. The Company directly performs or oversees via responsible vendors most criteria in general servicing, cash collection, and pool asset administration, demonstrating strong compliance in those areas. However, multiple investor remittances and reporting criteria (e.g., 1122(d)(3)(i)-(iv)), back-up servicer maintenance, and certain pool asset safeguards are marked as not performed by the Company or its subservicers, indicating reliance on unrelated parties or inapplicability.

• ·Several criteria (e.g., 1122(d)(1)(iii), 1122(d)(3)(i)-(iv), 1122(d)(4)(ii), 1122(d)(4)(xv)) explicitly marked as 'NOT performed by the Company or subservicers/vendors retained by the Company'.
• ·Reconciliations for bank accounts required within 30 calendar days after cutoff and resolved within 90 days.
• ·Funds held in trust analyzed at least annually; returned within 30 calendar days of repayment.

23-03-2026

Revenue from concentrate sales increased 64.6% YoY to $42.4M in 2025 from $25.8M in 2024, driven by 665 more ounces sold and higher realized gold prices of $3,583/oz versus $2,307/oz, boosting gross profit to $26.2M (61.8% margin) from $13.0M (50.3%) and net income to $16.6M from $8.8M. However, cash costs per ounce rose to $1,026 from $910 (+$117), all-in sustaining costs (AISC) per ounce climbed to $1,892 from $1,474 (+$418), exploration expenses surged $4.7M, and investing activities showed a $61.5M outflow versus $20.8M prior year.

• ·Realized gold price $3,583.43/oz in 2025 vs $2,306.86/oz in 2024.
• ·Cash and equivalents ended 2025 at $9.9M, up from $1.1M.
• ·Mineral resources estimated using $2,580/oz three-year trailing average gold price.

23-03-2026

Avalo Therapeutics' 10-K shows a sharp decline in cash and equivalents to $15.9M as of Dec 31, 2025 from $134.5M in 2024, driven by a net cash decrease of $118.6M versus a $127.1M increase prior year, with operating cash use rising 5% to $51.5M and financing inflows dropping 92% to $14.6M. Total assets fell 23% to $116.5M while stockholders' equity decreased 38% to $83.0M amid a $78.3M worsening of accumulated deficit to $(448.5M). However, interest income grew 31% to $4.4M and common shares outstanding more than doubled to 18.5M.

• ·Executives adopted Rule 10b5-1 trading plans in November 2025 for future sales of up to 471,718 shares total, expiring mid-to-late 2026.
• ·Derivative liability increased to $18.0M non-current (from $8.1M) with $9.5M negative fair value change in 2025.
• ·Series C Preferred Stock outstanding decreased to 18,792 shares from 24,896.

23-03-2026

Pyxis Oncology's total revenues declined 14% YoY to $13.9M in 2025 from $16.1M, primarily due to the complete loss of $8.1M royalty revenues despite growth in sale of royalty rights (+38% to $11.0M) and new milestone revenue of $2.8M. While total operating expenses fell 7% to $98.3M (no repeat of $21.0M impairment), R&D expenses rose 25% to $73.7M, resulting in a net loss widening to $79.6M from $77.3M; cash and equivalents dropped to $15.4M from $19.5M with higher operating cash burn of $63.5M.

• ·Rule 10b5-1 trading arrangement adopted by Lara Sullivan on Dec 22, 2025, for sale of 411,845 shares, effective until March 31, 2027.
• ·Marketable debt securities declined to $51.4M from $107.5M as of Dec 31, 2025.
• ·Stock-based compensation expense was $11.8M in 2025, down from $12.9M in 2024.
• ·Weighted average shares outstanding increased to 62.1M from 58.4M.

23-03-2026

Cabaletta Bio, Inc. reported a widened net loss of $167.9M for the year ended December 31, 2025, up 45% from $115.9M in 2024, primarily due to a 38% increase in total operating expenses to $172.2M driven by 47% higher R&D spending at $142.7M. Cash and cash equivalents fell 49% to $83.0M from $164.0M, with operating cash use rising 49% to $131.1M, though financing activities provided $100.3M mainly from stock issuances that nearly doubled shares outstanding to 100.5M. Total assets declined to $165.1M from $185.0M, with stockholders' equity dropping to $112.1M.

• ·Auditor emphasis of matter on accrued clinical trial expenses totaling $5.3M as of Dec 31, 2025 due to estimation uncertainty.
• ·Interest income declined 40% to $6.0M from $10.0M.
• ·Investing activities used $50.3M net cash in 2025 vs providing $47.3M in 2024, including $99.0M in investment purchases.
• ·Stock-based compensation increased 8% to $20.9M.

23-03-2026

Arbutus Biopharma Corp reported revenue of $14.1M for the year ended December 31, 2025, a 128% YoY increase from $6.2M in 2024, primarily driven by $10.4M from Qilu Pharmaceutical collaboration (up from $1.4M). However, the net loss narrowed to $33.5M from $69.9M amid reduced operating expenses ($52.2M vs. $82.5M), but was offset by elevated restructuring costs of $12.9M (up from $3.7M) and a cash balance decline to $18.0M from $36.3M.

• ·Net cash used in operating activities improved to $39.6M from $64.9M YoY.
• ·Contingent consideration liability related to 2014 Enantigen acquisition valued at $8.4M as of Dec 31, 2025.

23-03-2026

Solo Brands, Inc. reported net sales of $316.6M for the year ended December 31, 2025, down 30.4% YoY from $454.6M, with direct-to-consumer sales declining 37.0% to $200.9M and retail sales falling 14.6% to $115.6M. While gross profit margin improved to 59.4% from 57.3%, gross profit decreased 27.7% to $188.1M, and operating expenses dropped 30.7% to $301.6M amid restructuring; however, interest expense surged 89.7% to $26.6M. A segment reported net sales decline of 43.8% to $167.2M.

• ·Restructuring, Contract Termination and Impairment Charges declined 31.3% to $93.5M.
• ·Selling, general & administrative expenses down 32.8% to $176.2M.
• ·Income tax expense swung to $3.4M from benefit of $9.0M (change -138.2%).
• ·Segment direct-to-consumer net sales down 43.6% to $124.3M; retail down 44.1% to $42.9M.
• ·Segment cost of goods sold down 44.3% to $63.5M.

23-03-2026

Xilio Therapeutics reported collaboration and license revenue of $43.8M for the year ended December 31, 2025, a 590% YoY increase from $6.3M, which narrowed the net loss to $35.0M from $58.2M and improved loss per share to $(4.19) from $(15.24). However, total operating expenses rose 28% YoY to $85.7M, driven by R&D expenses up 36% to $56.0M and G&A up 20% to $29.7M. Cash and equivalents grew to $137.5M from $55.3M, supported by $87.8M in financing activities, though operating cash use remained at $(5.0M).

• ·Deferred revenue increased to $60.7M (current $40.0M + non-current $20.6M) from $32.8M.
• ·Common stock authorized shares increased to 600M from 200M.
• ·Stock-based compensation expense slightly up to $6.9M from $6.4M.
• ·Issuance of common stock and prefunded warrants to Gilead in prior period ($25.7M net); AbbVie stock purchase agreement in 2025 ($2.8M net).

23-03-2026

Talphera, Inc. reported research and development expenses of $6.0M for the year ended December 31, 2025, down 10% YoY from $6.7M, and selling, general, and administrative expenses of $7.5M, down 12% YoY from $8.5M, indicating effective cost reductions. However, total other expense net swung to a $0.9M loss from $2.2M income in 2024, a 139% decline driven by losses on warrant liability and absence of prior gains. Net cash used in operating activities improved to $11.4M from $12.7M YoY, but investing activities reflected a $14.3M outflow compared to a $3.8M inflow prior year.

• ·Gain on sale of future payments was $0 in 2025 vs. $1.2M in 2024 (-100%).
• ·(Loss) gain on change in fair value of warrant liability was $1.3M loss in 2025 vs. $0.7M gain in 2024 (-283%).
• ·Non-cash interest expense on liability related to sale of future payments was $0 in 2025 vs. $0.4M expense in 2024.
• ·Net cash provided by financing activities increased to $22.7M in 2025 from $12.0M in 2024.
• ·Ongoing capital needs include FDA regulatory applications and clinical trial completion for Niyad.

23-03-2026

Semtech Corp (SMTC) reported FY2026 net sales of $1.05B, up 15% YoY from $909M in FY2025, with strong growth in Infrastructure (+27%) and Signal Integrity (+23%). However, the Industrial segment's share of sales declined to 55% from 57%, IoT Systems and Connectivity gross margin fell to 35.5% from 39.3%, and total operating expenses rose 25% to 49% of net sales, driven by an $85M goodwill impairment (up over 1,000% YoY) and $1.8M intangible impairments. Overall gross margin improved modestly to 51.6% from 50.2%, while operating cash flow surged to $181M from $58M.

• ·Customer A represented 11% of FY2026 net sales (up from 10% in FY2025); Customer B 14% (up from 13%).
• ·Product development expenses up 15% YoY to 19% of sales; SG&A flat at ~21-24% of sales.
• ·Company operates 15 facilities totaling approximately 471,140 square feet across US, Canada, Switzerland, Taiwan, India, UK, and China.

23-03-2026

Yunhong Green CTI Ltd reported net sales growth of 10% YoY to $19.7M for the year ended December 31, 2025 from $18.0M in 2024, driven by foil balloons (+11% to $12.8M, 65% of sales) and film products (+33% to $1.1M), while other products grew modestly 4% to $5.8M. However, Customer B sales declined 8% to $7.9M (40% of revenues from 47%), the company recorded a $1.7M impairment on Hubei assets (vs $0 prior year), and depreciation doubled to $641k. Management remains focused on core foil balloon products and leveraging Yunhong Group advancements in compostable materials.

• ·Credit facility entered September 2021, extended in 2025, expires April 2028; in compliance since inception.
• ·55,600 shares under option outstanding and exercisable at Dec 31, 2025, weighted average exercise price $15.20 (unchanged from 2024).
• ·Two customers (A and B) represent 81% of 2025 revenues.

23-03-2026

Starwood Credit Real Estate Income Trust reported NAV of $310.5M as of December 31, 2025, supported by loans receivable at fair value of $1.39B. Total revenues surged 71% YoY to $82.5M driven by 75% higher interest income, leading to net income of $29.6M (up 286% YoY) and total distributions of $25.3M (up 126% YoY). However, interest expense rose 81% to $46.5M and there were unrealized losses on secured financings ($1.2M) and derivatives ($2.7M).

• ·Portfolio consists of 18 loans totaling $1.39B fair value, primarily multifamily (12 loans) and industrial (6 loans), with weighted average interest rate around 6.8%.
• ·Total maximum facility size for repurchase agreements: $1.55B, with $1.08B outstanding.
• ·Dividends per share: Class E $2.0148 (all ordinary), Class S $1.8430 (all ordinary), Class I $2.0148 (all ordinary).
• ·Unrealized gain on loans receivable: $4.4M; unrealized loss on secured financings: $1.2M; unrealized loss on derivatives: $2.7M.

23-03-2026

TGE Value Creative Solutions Corp, a SPAC formed on June 13, 2025, reported total assets of $150.8M as of December 31, 2025, primarily from $150.1M in trust account investments related to 15M Class A ordinary shares at $10.01 per share redemption value. The company recorded a net income of $146K for the period from inception through year-end, driven by $236K in other income including trust interest and fair value changes, despite a $90K operating loss. However, shareholders' deficit stood at $5.58M, largely due to $12M accretion of redeemable shares.

• ·Promissory note to related party: $150K
• ·Deferred underwriting commissions: $6M (non-current liability)
• ·Basic and diluted EPS for Class A and B shares: $0.03
• ·Class B shares initially issued to Sponsor: 5,750,000 for $25K, with 750,000 forfeited

23-03-2026

Appendix B of the BANK5 2023-5YR2 10-K filing details compliance assertions by multiple servicers (CWCAM, PBLS1, Midland, CoreLogic) with Regulation AB servicing criteria for asset-backed securities, primarily mortgage loan pools. Most applicable criteria are marked as performed directly by the company or responsible vendors, with several investor reporting and pool administration items designated as not applicable or not performed due to transaction structure. No material deficiencies or exceptions are reported across general servicing, cash collection, and asset administration categories.

• ·Filing date: March 23, 2026
• ·Standard timeframes referenced include deposits/postings within 2 business days, reconciliations within 30 calendar days, and resolution of reconciling items within 90 calendar days
• ·Multiple criteria (e.g., 1122(d)(1)(iii), 1122(d)(3)(ii)-(iv), various 1122(d)(4) items) marked as Not Applicable or Inapplicable across servicers

23-03-2026

Ultralife Corp (ULBI) reported FY2025 total revenues of $191.2M, up 16% YoY to $191.2M driven by strong 24% growth in Battery & Energy Products to $178.0M, however Communications Systems revenues declined 36% YoY to $13.1M. Gross profit rose 9% to $46.0M but operating expenses surged 60% to $51.9M, resulting in an operating loss of $5.9M and net loss of $5.9M versus prior year's profit of $6.3M; Adjusted EBITDA improved modestly 5% to $17.3M.

• ·Intangible asset impairment charge of $12.2M in FY2025.
• ·Cash increased to $9.3M from $6.9M as of Dec 31, 2025.
• ·Long-term debt decreased to $45.5M from $51.5M as of Dec 31, 2025.
• ·Total assets decreased 1.6% to $216.9M from $220.5M.
• ·EPS basic: -$0.35 vs +$0.38 YoY.

23-03-2026

Greenland Technologies Holding Corp. (GTEC) filed its 10-K annual report on March 23, 2026, reporting a total of 340 employees, with the largest group in production (275). The filing emphasizes significant operational and regulatory risks, including short product delivery lead-times that could lead to customer loss, tariffs on Chinese goods affecting HEVI-assembled products, volatile steel prices, PRC tax classification as a Resident Enterprise, restrictions on loans and investments in PRC subsidiaries, reliance on subsidiary dividends, currency conversion controls, limited U.S. regulatory oversight in China, potential Nasdaq delisting, and adverse effects from its dual-class share structure.

23-03-2026

Context Therapeutics Inc. (CNTX) reported a widened net loss of $36.1M for the year ended December 31, 2025, up 35% YoY from $26.7M, primarily due to a 40% surge in R&D expenses to $31.9M and 9% increase in G&A expenses to $7.8M, leading to a 33% higher operating loss of $39.7M. Cash and equivalents declined to $66.0M from $94.4M, with operating cash use rising to $26.4M from $14.6M; however, interest income grew modestly 6% to $3.4M. R&D breakdowns showed CT-202 expenses up sharply ~40% to $15.6M, CTIM-76 up ~23% to $6.8M, but CT-95 remained flat at ~$4.9M.

• ·Acquired in-process R&D charge of $2.0M in 2025 (down from $14.8M in 2024)
• ·Total assets decreased to $68.5M from $98.1M
• ·Stockholders' equity declined to $60.5M from $95.3M
• ·Accumulated deficit grew to $130.9M from $94.8M
• ·Net loss per share improved to $(0.38) from $(0.46)

23-03-2026

SilverBox Corp V, a SPAC, reported its financial position as of December 31, 2025, with $276.8M held in the Trust Account from 27.6M redeemable Class A shares at $10.03 per share, providing strong liquidity for its initial business combination. However, the company recorded a net loss of $7.7M for the period from inception (May 29, 2025) through year-end, primarily due to an $8.3M advisory fee expense and $8.3M deferred underwriting fee, resulting in a shareholders' deficit of $19.3M.

• ·Operating and formation costs: $153K
• ·Gain on warrant liabilities: $102K
• ·Transaction costs: $127K
• ·Interest earned on Trust Account: $769K
• ·Basic and diluted net loss per share (Class A and B): $0.80
• ·Lock-up on founder shares releases if share price >= $12.00 for 20 trading days within any 30-trading day period starting 150 days post-business combination

23-03-2026

Aardvark Therapeutics reported a significantly widened net loss of $57.6M for 2025 compared to $20.6M in 2024, driven by R&D expenses surging 182% YoY to $48.9M and G&A up 160% to $13.8M amid clinical development ramp-up. However, the company completed its IPO raising net proceeds of $87.5M, converting all convertible preferred stock and flipping stockholders' equity from a $54.6M deficit to $106.6M positive, though cash and equivalents declined 24% to $47.1M with net cash burn of $14.6M.

• ·IPO underwriting discounts and issuance costs totaled $10.4M.
• ·Convertible preferred stock fully converted to common stock upon IPO, eliminating $126.8M liquidation preference.
• ·External R&D costs increased to $36.0M from $12.7M YoY.
• ·Net cash provided by financing activities $89.2M in 2025 vs $82.0M in 2024.
• ·Audited by BDO USA, P.C. (PCAOB ID #243).

23-03-2026

The 10-K annual report for BANK 2017-BNK7 includes Appendix B, asserting compliance with Regulation AB Rule 1122(d) servicing criteria for asset-backed securities. Most criteria in general servicing considerations, cash collection, and pool asset administration are performed directly by the servicer or responsible vendors, while several investor remittances and reporting criteria (e.g., 1122(d)(3)(i)-(iv)) are not performed by the company or its subservicers. Criteria like back-up servicer maintenance (1122(d)(1)(iii)) and pool asset safeguarding (1122(d)(4)(ii)) are marked as not performed or inapplicable.

23-03-2026

NRX Pharmaceuticals reported its first net patient service revenue of $1.2M in 2025 from HOPE Therapeutics clinics, a significant improvement from $0 in 2024, with R&D expenses declining 39% YoY to $3.8M and operating loss narrowing 12% to $16.2M. However, net loss widened 14% YoY to $28.6M due to higher other expenses including $4.9M in warrant liability fair value changes and $6.2M loss on convertible note conversions. Key progress includes positive FDA feedback on KETAFREE™ ANDA targeting Q3 2026 launch in a $750M market and planned NRX-100 NDA filing in Q2 2026 for a $2B depression market.

• ·HOPE clinics established in Naples FL, Fort Myers FL, West Palm Beach FL, Sarasota FL (2), with development in Boston MA, Denver CO.
• ·ANDA for KETAFREE™ filed Sept 2025; FDA communications Nov 6 2025 and March 15 2026 indicate no deficiencies.
• ·NDA for NRX-100 expected Q2 2026 following Fast Track Designation.
• ·RWE from 65,000 IV ketamine patients vs 6,000 S-ketamine patients supports faster onset for IV ketamine.

23-03-2026

Surrozen reported total revenue of $3.5M for 2025, down 67% YoY from $10.7M, driven by the complete loss of $10M collaboration and license revenue, though related-party research service revenue rose significantly to $3.5M from $0.7M. Operating expenses increased 26% to $45.6M, leading to a sharply wider net loss of $242M versus $64M in 2024, exacerbated by large non-cash charges from 2025 PIPE execution ($71M loss) and tranche liability fair value changes ($105M loss). Cash and equivalents grew to $89.2M from $34.6M, supported by $85.1M in financing inflows, but cash burn from operations worsened to $30.2M from $17.6M.

• ·Stockholders’ deficit widened to ($187.8M) from ($21.4M).
• ·Tranche liability stood at $158.7M and warrant liabilities at $112.5M as of Dec 31, 2025.
• ·Net loss per share $32.37 (basic and diluted) vs $21.67 in 2024.
• ·Proceeds from 2025 PIPE issuance $74.7M net of costs.

23-03-2026

Battalion Oil Corp's 10-K filing discloses proved reserves of 59,702 MBoe (35,649 MBoe developed, 24,053 MBoe undeveloped) with PV-10 value of $351.7M as of December 31, 2025. Recent developments include a $15M private placement equity offering closed March 4, 2026, and the West Quito divestiture closed February 24, 2026, for adjusted proceeds of $60.1M, with $45.6M used for debt repayment; however, the company has no additional borrowing capacity under its 2024 Amended Term Loan Agreement and faces $22.5M in near-term debt maturities in 2026.

• ·Reinvestment Proceeds of $12.9M must be used within 180 days after receipt for specific acquisitions, capital expenditures, or debt prepayment.
• ·Hedging program employed to reduce cash flow variability.
• ·2024 Amended Term Loan Agreement has no additional borrowing capacity as of December 31, 2025.

23-03-2026

Merrill Lynch Depositor Inc IndexPlus Trust Series 2003-1 (IPB) filed its 10-K annual report on March 23, 2026, covering standard sections including Business, Risk Factors, MD&A, Financial Statements, and Controls and Procedures. The filing includes exhibits such as the Trustee's Annual Compliance Certificate (EX-99.1), reports from PricewaterhouseCoopers LLP (EX-99.2) and KPMG LLP (EX-99.3), Insider Trading Policy (EX-19), and Compensation Recovery Policy (EX-97). No quantitative financial data or period-over-period comparisons are detailed in the provided table of contents.

23-03-2026

Sutro Biopharma's revenue grew 65% YoY to $102.5M in 2025 from $62.0M in 2024, primarily driven by $56.4M from new partner Ipsen, though offset by declines from Astellas (-14%), Tasly (-98%), and Vaxcyte (-77%). Net loss narrowed 16% to $191.1M from $227.5M, with total operating expenses down 13% due to R&D reductions (-34%), but new $53.4M restructuring costs emerged; however, cash and equivalents plummeted to $58.1M from $190.3M, with a net cash decrease of $132.2M versus a $121.0M increase prior year, and stockholders' equity shifted to a $132.5M deficit from a $44.6M surplus.

• ·Cash used in operating activities improved to $177.2M from $191.5M YoY.
• ·Non-cash interest expense on royalty sale increased 23% to $38.2M from $31.1M.
• ·Weighted-average shares for net loss per share: 8,497,798 in 2025 vs. 7,736,734 in 2024; net loss per share improved to ($22.49) from ($29.40).

23-03-2026

PPLUS Trust Series GSC-2 (PYT) filed its 10-K annual report on March 23, 2026, including standard sections such as Business, Risk Factors, MD&A, Financial Statements, and governance disclosures across Parts I-IV. Exhibits feature the Trustee's Annual Compliance Certificate, Insider Trading Policy, compensation recovery policy, and reports from auditors PricewaterhouseCoopers LLP and KPMG LLP. No specific financial metrics, period-over-period comparisons, or performance data are detailed in the provided table of contents.

23-03-2026

Bold Eagle Acquisition Corp., a SPAC, reported net income of $9.8M for the year ended December 31, 2025, up 378% YoY from $2.0M, driven by interest income on Trust Account investments surging to $10.8M from $2.0M as the Trust balance grew to $269.8M. However, general and administrative expenses rose sharply 310% YoY to $1.0M from $0.25M, widening operating losses to $1.0M, while shareholders’ deficit slightly worsened to $7.9M from $7.9M. Total assets increased to $270.6M, primarily from Trust growth, but current assets declined 13% YoY to $0.3M.

• ·Class A redeemable shares redemption value: $10.35 per share (Dec 31, 2025) vs $10.04 (Dec 31, 2024)
• ·Promissory note - related party: flat at $543K both periods
• ·Deferred underwriting commissions: flat at $9.0M both periods
• ·Basic and diluted EPS for Class A redeemable and non-redeemable shares: $0.31 (2025) vs $0.21 (2024)

23-03-2026

For the six months ended January 31, 2026, Concrete Leveling Systems Inc reported revenue of $55,150, a massive 17,913% YoY increase from $308, swinging to net income of $862 from a $37,499 loss, driven by higher sales and operational income of $5,365. However, the three months ended January 31 showed revenue growth of 20% to $150 but a widened net loss of $15,817 from $12,696 YoY due to elevated operating expenses of $13,704. Cash improved significantly to $19,749 from $824 at July 31, 2025, though current liabilities rose to $662,730 amid heavy related-party debt.

• ·Gross margin for six months ended Jan 31, 2026: $54,089 (98% of sales) vs $239 prior year.
• ·Operating expenses for three months: $13,704 in 2026 vs $10,227 in 2025, driven by legal fees $11,310 vs $7,450.
• ·Net cash from operating activities six months: $20,059 in 2026 vs used $210 in 2025.
• ·Purchase of PPE: $1,134 in six months ended Jan 31, 2026.
• ·Accrued interest - stockholders: $60,918 as of Jan 31, 2026 vs $56,416 at July 31, 2025.

23-03-2026

Lument Finance Trust reported a net loss of $7.5M for FY 2025 attributable to common stockholders, compared to a $17.9M profit in FY 2024, with Q4 2025 loss widening to $8.9M; dividends declared per share fell to $0.22 for the year from $0.40 YoY. The loan portfolio grew with unpaid principal balance (UPB) increasing 7% YoY to $1.14B and LTV improving to 68.9% from 72.5%, though loan count declined to 61 from 65, weighted average coupon dropped to 7.2% from 8.1%, and allowance for credit losses doubled to $22.7M. Total stockholders' equity decreased to $219M from $238M, with book value per share at $3.03 down 11% from $3.40.

• ·Loan portfolio consists entirely of floating rate senior secured loans (100%).
• ·Acquired real estate owned properties totaling $51M ($26.8M held-for-investment, $24.1M held-for-sale) as of Dec 31, 2025.
• ·Dividends per share trended downward quarterly in 2025, from $0.08 in Q1 to $0.04 in Q4.

23-03-2026

Planet Labs PBC's FY2026 revenue grew 26% YoY to $307.7M from $244.4M, with gross profit up 23% to $172.5M and operating loss improving 18% (narrowing) to $95.1M; Adjusted EBITDA turned positive at $15.5M versus a $10.6M loss prior year. However, net loss more than doubled to $246.9M from $123.2M, driven by a $161.4M unfavorable change in fair value of warrant liabilities, while gross margin slipped to 56% from 57% and stockholders' equity declined to $188.4M from $441.3M.

• ·Cash flow from operating activities improved to $134.4M from ($14.4M) YoY.
• ·Cash and cash equivalents increased to $229.4M from $118.0M; short-term investments to $410.6M from $104.0M.
• ·Deferred revenue rose sharply to $248.1M ($220.6M current + $27.5M non-current) from $93.5M.
• ·Public and private placement warrant liabilities at $173.3M current as of Jan 31, 2026.

23-03-2026

Evergy Missouri West Storm Funding I, LLC, a wholly-owned bankruptcy remote subsidiary of Evergy Missouri West, Inc., filed its annual 10-K for the fiscal year ended December 31, 2025, omitting most sections including financial statements and MD&A pursuant to General Instruction J for asset-backed securities issuers. The filing discloses managers and executive officers, including Geoffrey T. Ley as Manager and President, and notes an annual independent manager fee of $3,700 paid to Corporation Service Company. Compliance with servicing criteria is affirmed through referenced exhibits, with no unresolved issues or material changes reported.

• ·Filing covers fiscal year ended December 31, 2025, with report signed March 23, 2026.
• ·Entity established with key agreements dated February 23, 2024, including Indenture and Servicing Agreement.

23-03-2026

For the nine months ended January 31, 2026, Sparta Commercial Services reported total revenue of $288,157, up 71% YoY from $168,357, driven by strong growth in merchant financing (+192% to $158,705), while information technology (+15% to $100,496) and wellness products (+10% to $28,956) showed modest gains; however, the company posted a net loss of $1.4M, improved from $1.8M YoY but still reflecting high operating expenses and interest costs. Balance sheet shows total assets at $933K (up 23% from $757K), but cash declined 47% to $70K, liabilities rose to $12.1M, and stockholders' deficit worsened to $11.2M. Operating cash use improved to $725K from $1.2M, funded by $664K in financing activities.

• ·Current portion notes payable increased to $8.99M from $7.97M as of Jan 31, 2026 vs Apr 30, 2025.
• ·Derivative liabilities decreased to $968K from $1.01M.
• ·Weighted average shares outstanding for nine months: 42.88M vs 33.95M prior year.
• ·Net cash provided by financing activities: $664K vs $1.13M prior year.

23-03-2026

TPG Private Equity Opportunities, L.P. (T-POP) reported a net increase in net assets from operations of $135.2M for the year ended December 31, 2025, driven by $170M in unrealized gains on investments, with total net assets reaching $1.02B from $0 in 2024 following $897M in unit issuance proceeds. However, the fund recorded a net investment loss of $33.0M as total expenses of $35.5M significantly exceeded revenues of $2.6M, and cash balances remained at $0 despite offsetting operating and financing cash flows. NAV per unit increased across classes, delivering total returns of 18.7% to 24.5%.

• ·Cash and cash equivalents remained at $0 at period end.
• ·Deconsolidation of T-POP US Aggregator (CYM), L.P. impacted changes by $(2.6M).
• ·Organizational expenses: $7.4M; Performance Participation Allocation: $19.3M.
• ·T-POP US Aggregator commenced operations June 2, 2025.